Celyad SA


Prices are adjusted according to historical splits.

Celyad SA Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$21.14 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Celyad SA had its IPO on 2015-06-19 under the ticker symbol CYAD.

The company operates in the Healthcare sector and Biotechnology industry. Celyad SA has a staff strength of 95 employees.

Stock update

Shares of Celyad SA opened at $0.83 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $0.83 - $0.96, and closed at $0.88.

This is a +1.23% increase from the previous day's closing price.

A total volume of 4,147 shares were traded at the close of the day’s session.

In the last one week, shares of Celyad SA have slipped by -6.3%.

Celyad SA's Key Ratios

Celyad SA has a market cap of $21.14 million, indicating a price to book ratio of 0.6921 and a price to sales ratio of 12738.134.

In the last 12-months Celyad SA’s revenue was $0 with a gross profit of $5000 and an EBITDA of $-28706000. The EBITDA ratio measures Celyad SA's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Celyad SA’s operating margin was 0% while its return on assets stood at -29.33% with a return of equity of -92.64%.

In Q2, Celyad SA’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Celyad SA’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celyad SA’s profitability.

Celyad SA stock is trading at a EV to sales ratio of 11209.6676 and a EV to EBITDA ratio of -0.4501. Its price to sales ratio in the trailing 12-months stood at 12738.134.

Celyad SA stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$63.14 million
Total Liabilities
$11.36 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Celyad SA ended 2023 with $63.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $63.14 million while shareholder equity stood at $30.65 million.

Celyad SA ended 2023 with $441000.00 in deferred long-term liabilities, $11.36 million in other current liabilities, 78585000.00 in common stock, $-323053000.00 in retained earnings and $883000.00 in goodwill. Its cash balance stood at $14.39 million and cash and short-term investments were $14.39 million. The company’s total short-term debt was $783,000 while long-term debt stood at $0.

Celyad SA’s total current assets stands at $19.38 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $3.72 million compared to accounts payable of $6.01 million and inventory worth $0.

In 2023, Celyad SA's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Celyad SA paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Celyad SA stock is currently trading at $0.88 per share. It touched a 52-week high of $3.07 and a 52-week low of $3.07. Analysts tracking the stock have a 12-month average target price of $8.52.

Its 50-day moving average was $1.23 and 200-day moving average was $1.38 The short ratio stood at 0.23 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 2915.5% are held by institutions.

Frequently Asked Questions About Celyad SA

The stock symbol (also called stock or share ticker) of Celyad SA is CYAD

The IPO of Celyad SA took place on 2015-06-19

Similar Industry Stocks (Biotechnology)

Last Price
Ipsidy Inc (AUID)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company’s preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.


Axis Business Park, Mont-Saint-Guibert, Belgium, 1435